Compound profile
Sermorelin
Limited human dataAlso known as: GRF 1-29 · GHRH 1-29 · Geref
A 29-amino-acid fragment of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release the body's own growth hormone. Once an FDA-approved drug for pediatric growth hormone deficiency, it is now mostly used off-label and compounded for adult anti-aging and GH-optimization protocols.
Overview
Sermorelin is the first 29 amino acids of endogenous GHRH, the shortest fragment of the hormone that retains full biological activity. Serono developed it under the brand name Geref, and the FDA approved it in 1997 to diagnose and treat growth hormone deficiency in children. Serono discontinued the branded product in 2008 for business reasons unrelated to safety, and since then sermorelin has lived on mainly as a compounded peptide sold through anti-aging and hormone-optimization clinics.
Unlike synthetic GH secretagogues that bind the ghrelin receptor, sermorelin works through the GHRH receptor, the same pathway the body uses naturally. That distinction matters to how it's discussed: because it works upstream of the pituitary's own GH-release machinery, proponents argue it preserves the pulsatile, physiological pattern of GH secretion rather than forcing a large synthetic spike.
It shows up constantly in conversations alongside CJC-1295 and tesamorelin, the other GHRH-class peptides, and is often positioned as the gentler, shorter-acting option of the three because of its very short half-life. Its clinical history as an approved pediatric drug also gives it a more established pharmacology and safety record than most peptides discussed for adult off-label use.
Mechanism (plain language)
Binds GHRH receptors on pituitary somatotrophs, triggering cAMP-mediated release of stored growth hormone in a pulsatile pattern that mimics the body's natural GH rhythm rather than a single large surge.
How it works
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, the same receptor endogenous GHRH activates. This triggers a rise in intracellular cAMP, which drives the release of stored growth hormone into the bloodstream. Because sermorelin still requires a functioning pituitary and an intact hypothalamic feedback loop, it stimulates the body's own GH secretion rather than replacing it directly, which is the key mechanistic difference from injecting recombinant human growth hormone.
Its plasma half-life is only about 11 to 12 minutes, so its action is brief and closely tied to the timing of the dose. In practice this means sermorelin tends to produce a pulse of GH release rather than a sustained elevation, which is part of why it's often discussed as preserving a more physiological secretion pattern than longer-acting secretagogues. Negative feedback from somatostatin and rising IGF-1 still constrains how much GH sermorelin can trigger at any given dose, which is thought to lower the risk of excessive, unchecked GH elevation compared with direct GH administration.
What research suggests
Older clinical trials in children with GH deficiency and in healthy older adults show it reliably raises GH and IGF-1 levels. Data specifically on body composition, recovery, or longevity outcomes in healthy adults using it off-label remains thin.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Restored GH and IGF-1 levels
Clinical trials in older men and women report that nightly GHRH(1-29) injections reverse age-related declines in GH and IGF-1, bringing levels closer to those seen in younger adults.
Approved efficacy in pediatric GH deficiency
As Geref, sermorelin was shown to stimulate GH secretion in children with GH deficiency without significantly altering prolactin, cortisol, thyroid hormone, or glucose levels, which supported its original FDA approval.
Physiological secretion pattern
Because it acts upstream through the GHRH receptor rather than forcing GH release directly, it is thought to preserve the pulsatile timing of natural GH secretion rather than producing a single large spike.
Uncertainties & risks
Most of the strongest data comes from short trials in children with diagnosed GH deficiency or in older adults using it as a research tool, not from healthy adults using it off-label for body composition or longevity. Long-term safety and efficacy data for the compounded product sold today, as opposed to the discontinued branded drug, is limited.
In the original clinical trials, sermorelin was generally well tolerated, with injection-site reactions, flushing, and headache being the most commonly reported issues, and no significant changes seen in other pituitary hormones or glucose metabolism at studied doses. Because it depends on a working pituitary, it will not raise GH in people whose pituitary somatotrophs are severely damaged or absent, which limits its use compared with direct GH replacement in some deficiency states. The compounded sermorelin sold today is not the same regulated product as the discontinued Geref, so purity, dosing consistency, and sourcing vary by pharmacy. As with other GH-axis peptides, questions about long-term effects on insulin sensitivity and cancer risk from sustained IGF-1 elevation remain open research questions rather than settled findings.
Side effects
Commonly reported
- Injection-site redness or irritation: Reported in pediatric and adult GHRH trials
- Flushing or warmth after injection: Transient, tied to the timing of the dose
- Headache: Reported in a subset of trial participants
Reported in the cited literature, not a complete list, and not medical advice. Individual responses vary; consult a qualified professional.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.